RxDoctor Payments Data

Maria Hella, MD

Neurology · Jacksonville, FLNPI 1003903949

Payments from drug & device makers

$6,208in general payments, 2019–2025

Across 227 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$767
  • UCB, Inc.$643
  • AbbVie$506
  • Amgen$502
  • Neurelis, Inc.$333
  • Biogen$282
  • plus $3K from 40 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$6,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,208 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$96,723
Medicare patients
362
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)36$155,688
XcopriCenobamate21$65,521
VimpatLacosamide30$57,986
Lamictal XrLamotrigine12$54,899
ValtocoDiazepam22$40,681
FycompaPerampanel21$32,136
BriviactBrivaracetam13$28,328
Keppra XrLevetiracetam11$26,884
NayzilamMidazolam12$21,140
Lacosamide119$16,292
DepakoteDivalproex Sodium17$13,868
Levetiracetam ErLevetiracetam194$13,341
Levetiracetam302$10,231
Lamotrigine ErLamotrigine29$6,132
DilantinPhenytoin Sodium Extended25$5,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat, Briviact, Nayzilam$643$107,45455 claims
SK Life Science, Inc.Xcopri$767$65,52121 claims
Neurelis, Inc.Valtoco$333$40,68122 claims
Eisai Inc.Fycompa$198$32,13621 claims
PfizerDilantin$260$5,44925 claims
Upsher-smith Laboratories LLCTopiramate$25$1,41965 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →